Cargando…

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer

Adrenocortical carcinoma (ACC) is a rare orphan disease with a dismal prognosis. Surgery remains the first-line treatment, but most patients eventually develop metastatic disease. Mitotane is often used with chemotherapy with modest success. Little information is available concerning the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Head, Lia, Kiseljak-Vassiliades, Katja, Clark, Toshimasa J, Somerset, Hilary, King, Jonathan, Raeburn, Christopher, Albuja-Cruz, Maria, Weyant, Michael, Cleveland, Joseph, Wierman, Margaret E, Leong, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853671/ https://www.ncbi.nlm.nih.gov/pubmed/31745526 http://dx.doi.org/10.1210/js.2019-00305

Ejemplares similares

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report
por: Schreiber, Anna R, et al.
Publicado: (2020)

SUN-337 Anti-tumorigenic Effects Of The Maternal Leucine Zipper Kinase (MELK) Inhibitor, OTSSP167, In Pre-clinical In Vivo Models Of Adrenocortical Carcinomas (ACC)
por: KAR, ADWITIYA, et al.
Publicado: (2019)

The Immunotherapy Landscape in Adrenocortical Cancer
por: Pegna, Guillaume J., et al.
Publicado: (2021)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Insights From Targeted Genetic Analysis of 364 Adrenocortical Carcinomas
por: Pozdeyev, Nikita, et al.
Publicado: (2021)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction
por: Weigand, Isabel, et al.
Publicado: (2020)

SUN-211 Active Steroid Hormone Synthesis Renders Adrenocortical Cells Highly Susceptible to Type II Ferroptosis Induction
por: Weigand, Isabel, et al.
Publicado: (2020)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
por: Oddie, Philip D, et al.
Publicado: (2018)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2021)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

OR04-6 Comprehensive Profiling of the MELK Inhibitor OTSSP167's Action and Its Effect on Sensitization to Wee1 Inhibitor AZD1775 in a Spectrum of ACC Models
por: Bagby, Stacey, et al.
Publicado: (2022)

Association of Cigarette Smoking with Aberrant Methylation of the Tumor Suppressor Gene RARβ2 in Papillary Thyroid Cancer
por: Kiseljak-Vassiliades, Katja, et al.
Publicado: (2011)

Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing’s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane
por: Greb, Alexandra C, et al.
Publicado: (2021)

Unwanted Hormonal and Metabolic Effects of Postoperative Adjuvant Mitotane Treatment for Adrenocortical Cancer
por: Basile, Vittoria, et al.
Publicado: (2020)

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment
por: Puglisi, Soraya, et al.
Publicado: (2019)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study
por: Mormando, Marilda, et al.
Publicado: (2023)

Preclinical Models of Adrenocortical Cancer
por: Sedlack, Andrew J. H., et al.
Publicado: (2023)

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
por: Haak, H. R., et al.
Publicado: (1994)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing
por: Yin, Anyue, et al.
Publicado: (2020)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2022)

Effects of o,p’-DDE, a Mitotane Metabolite, in an Adrenocortical Carcinoma Cell Line
por: Bach, Camila, et al.
Publicado: (2022)

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma
por: Weng, Yan, et al.
Publicado: (2023)

CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells
por: Germano, Antonina, et al.
Publicado: (2018)

Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis
por: Tang, Yongquan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_497dpja67tns9ik7n3ent5dtm6